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While the guidelines for vaccination in renal transplant
recipients recommend the use of pneumococcal
polysaccharide (PPS) and tetanus toxoid (TT), their efficacy
in immunocompromised renal transplant recipients is not
known. Here we tested the effect of everolimus on immune
responses after vaccination by measuring the capacity of
36 stable renal transplant recipients to mount cellular and
humoral responses after vaccination. Twelve patients in each
treatment arm received immunosuppressive therapy
consisting of prednisolone (P) plus cyclosporine (CsA),
mycophenolate sodium (MPA), or everolimus. Patients
were vaccinated with the T-cell-dependent antigens
immunocyanin and TT, and the T-cell-independent PPS.
Treatment with CsA partially inhibited and MPA completely
abolished the capacity to mount a primary humoral response,
whereas everolimus left this largely intact. Recall responses
were inhibited by MPA only. All drug combinations inhibited
cellular responses against TT. In patients treated with MPA,
B-cell numbers were severely reduced. Thus, combined with
P, treatment with MPA completely disturbed primary and
secondary humoral responses. Everolimus or CsA allowed the
boosting of T-cell-dependent and -independent secondary
humoral responses. Treatment with everolimus allowed
a primary response.
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Current immunosuppressive drug regimens after renal
transplantation have improved allograft survival at the
expense of more profound immunosuppression, as apparent
from an increased risk of infectious complications.1–3
Guidelines for immunizations in renal transplant patients
have been established by the American Society of Transplan-
tation, recommending immunization with pneumococcal
polysaccharide (PPS), tetanus toxoid (TT), and influenza.4
The use of live vaccines is contraindicated. Despite these
guidelines, there continues to be a gap between guidelines
and clinical practice.5 A main reason for non-vaccination is
the absence of a doctors’ recommendation.6 This may be
owing to concerns that vaccination might trigger allograft
rejection.7,8 However, this concern is unfounded.9,10 Another
reason might be doubts about efficacy in immunosuppressed
patients. Different immunosuppressive regimens vary in their
effects on cellular and humoral responses after vaccination.
Most studies on humoral responses after vaccination have
been performed in the prednisolone (P), azathioprine, and
cyclosporine (CsA) era.11–13 Previously, we demonstrated that
stable renal transplant recipients treated with double
immunosuppressive therapy consisting of P and CsA mount
normal antigen-specific antibody responses after vaccination
with keyhole limpet hemocyanin and TT. In contrast, patients
treated with mycophenolic acid (MPA), as part of a triple
immunosuppressive maintenance regimen showed severely
reduced antibody responses after vaccination.14 Recently,
Candon et al.10 showed diminished antibody responses to
influenza vaccination in renal transplant recipients treated with
steroids, MPA, or azathioprine, in combination with tacroli-
mus, CsA, or sirolimus, whereas interferon (IFN)-g T-cell
responses were conserved. Willcocks et al.15 demonstrated
similar efficacy of vaccination with PPS and influenza in renal
transplant recipients treated with a calcineurin inhibitor- or
sirolimus-containing immunosuppressive regimen. Everolimus,
like sirolimus, is a mammalian target of rapamycin inhibitor,
which is effective in the prevention of renal allograft
rejection3,16 and has a different side effect profile compared
with CsA and MPA.17,18 The effect of everolimus on human
responses to vaccination in vivo has not been studied until now.
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We recently performed a randomized prospective trial in
renal transplant recipients starting on induction therapy
with an interleukin (IL)-2 receptor antagonist, followed by a
triple immunosuppressive regimen. Immunosuppression was
tapered after 6 months to double therapy with P combined
with CsA, mycophenolate sodium (MPA), or everolimus.19 In
this study, we tightly monitored exposure to CsA, MPA, and
everolimus. In a subgroup of these patients, we assessed the
capacity to mount cellular and humoral immune responses
after vaccination. In addition, phenotyping of peripheral B
cells was performed to analyze the effects of the different




A total of 36 renal transplant recipients, 12 in each treatment
arm, and 13 healthy control individuals were included in this
study. Baseline clinical characteristics are summarized in
Table 1. Patient groups and healthy control individuals were
comparable for age and sex. There was no difference in renal
function between the patient groups and no acute rejection
episodes had occurred.
Primary humoral response after vaccination with
immunocyanin
Mean (±s.d.) immunocyanin-specific immunoglobulin (Ig)
G antibody levels before vaccination were 737±456 in
healthy control individuals; 897±513 in P/CsA-treated
patients; 542±332 in P/MPA-treated patients; and 392±
201 in P/everolimus-treated patients. Following vaccination,
mean antigen-specific IgG antibody levels rose significantly in
healthy control individuals (Po0.0005; Figure 1a) and
in patients receiving P/everolimus (Po0.05). In patients
treated with P/CsA or P/MPA, there was no significant
increase in antigen-specific IgG antibody levels.
The primary humoral response against immunocyanin,
measured as the difference between post- and pre-vaccination
immunocyanin-specific IgG antibody levels, was significantly
reduced in all patient groups as compared with healthy
control individuals (Po0.0005). There was no difference in
response between the patient groups.
Secondary humoral response after vaccination with TT
Mean (±s.d.) TT-specific IgG antibody levels before
vaccination were 2.35±1.86 in healthy control individuals;
1.31±1.56 in P/CsA-treated patients; 1.24±1.46 in P/MPA-
treated patients; and 0.87±1.13 in P/everolimus-treated
patients. Following vaccination, mean antigen-specific
IgG antibody levels rose significantly in healthy control
individuals (Po0.0005; Figure 1b), in patients receiving
P/CsA (Po0.005), and in patients treated with P/everolimus
(Po0.0005). In patients treated with P/MPA, there was
no significant increase in antigen-specific IgG antibody
levels.
The secondary humoral response against TT, measured as
the difference between post- and pre-vaccination TT-specific
IgG antibody levels, was significantly reduced in patients
treated with P/CsA and P/MPA as compared with healthy
control individuals (Po0.05, Po000.5, respectively).
Patients treated with P/MPA also showed a significantly
decreased response as compared with patients receiving
P/everolimus (Po0.005). In patients receiving P/everolimus,
the humoral response against TT was not reduced compared
with healthy control individuals.
Secondary humoral response after vaccination with PPS
Mean (±s.d.) PPS-specific IgG antibody levels before
vaccination were 138.4±162.5 in healthy control individuals;
50.3±45.9 in P/CsA-treated patients; 46.2±35.2 in P/MPA-
treated patients; and 102.4±82.4 in P/everolimus-treated
patients. Following vaccination, mean antigen-specific
IgG antibody levels rose significantly in healthy control
individuals (Po0.0005; Figure 1c), in patients receiving
P/CsA (Po0.0005), and in patients treated with P/ever-
olimus (Po0.0005). In patients treated with P/MPA,
Table 1 | Characteristics of patients and healthy control individuals
P/CsA P/MPA P/everolimus HC P-value
Number of patients 12 12 12 13
Age (years, median range) 58 (34–72) 60 (30–70) 50 (27–68) 55 (42–63) NS
Male (n, %) 10 (83) 9 (75) 8 (67) 8 (62) NS
First/second transplant 11/1 11/1 12/0 — NS
Acute rejection (%) 0 0 0 — NS
End-stage renal disease
Unknown 2 1 1
Adult polycystic kidney disease 2 3 1
Renal vascular disease 1 5 4
Pyelonephritis 2 1 1
Vasculitis 1 1 —
Glomerular 3 — 5
Other 1 1 —
Renal function GFRa (ml/min) 49 (27–93) 59 (26–100) 59 (30–85) NA NS
Abbreviations: CsA, cyclosporine; GFR, glomerular filtration rate; HC, healthy control individuals; MPA, mycophenolate sodium; NA, not available; NS, not significant;
P, prednisolone.
aGFR estimated by the modification of diet in renal disease.
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there was no significant increase in antigen-specific IgG
antibody levels.
The secondary humoral response against PPS, measured
as the difference between post- and pre-vaccination PPS-
specific IgG antibody levels, was significantly reduced in
patients receiving P/CsA as compared with healthy control
individuals (Po0.05). Patients treated with P/MPA showed a
significantly decreased response as compared with healthy
control individuals (Po0.0005) and with patients receiving
P/CsA (Po0.05) or P/everolimus (Po0.005). In patients
receiving P/everolimus, the humoral response against PPS
was not reduced compared with healthy control individuals.
Cellular responses after in vitro stimulation with TT
TT-specific cellular responses in vitro, as assessed by enzyme-
linked immunospot (ELISPOT) assay, are shown in Table 2.
Non-specific stimulation with phytohaemagglutinin showed
no difference in the number of responsive peripheral blood
mononuclear cells (PBMCs) at both time points for
all cytokines either in the healthy control individuals or in
any patient group (data not shown).
The mean (±s.d.) numbers of IL-2-producing cells before
vaccination were: healthy control individuals 2.8±3.0, P/CsA
0.8±1.5, P/MPA 3.4±3.2, and P/everolimus 2.8±4.6. After
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Figure 1 |Humoral responses against immunocyanin, TT, and PPS. Humoral responses against (a) immunocyanin, (b) tetanus toxoid
(TT), and (c) pneumococcal polysaccharide (PPS). Mean antigen-specific immunoglobulin (Ig) G antibody levels before and 14 days after
vaccination were analyzed by enzyme-linked immunosorbent assay. Statistical comparison of the antigen-specific IgG levels before and 14
days after vaccination: *Po0.05, **Po0.005, ***Po0.0005. The first column shows the prednisolone (P)/cyclosporine-treated patients; the
second column shows patients treated with P/MPA; the third column shows patients receiving P/everolimus; the last column shows the
healthy control individuals. NS, not significant.
Table 2 | Number of IL-2-, IFN-c-, and IL-4-producing cells after in vitro stimulation with tetanus toxoid
IL-2 IFN-c IL-4
Day 0 Day 14 Day 0 Day 14 Day 0 Day 14
P/CsA 0.8±1.5 4.7±5.8** 5.2±10.8 10.0±10.6* 0.2±0.4 6.3±11.7*
P/MPA 3.4±3.2 5.4±6.1 1.4±2.9 5.2±5.1 0.1±0.4 5.0±5.8*
P/everolimus 2.8±4.6 6.7±7.5* 10.6±20.6 6.4±8.6 2.0±3.1 5.6±7.2*
HC 2.8±3.0 14.0±7.0*** 11.1±12.4 38.1±30.1** 0.3±0.5 19.8±11.4***
Abbreviations: CsA, cyclosporine; HC, healthy control individuals; IFN, interferon; IL, interleukin; MPA, mycophenolate sodium; P, prednisolone.
Statistical comparison of the mean (±s.d.) number of cytokine-secreting cells before and 14 days after vaccination: *Po0.05, **Po0.005, ***Po0.0005. Results were corrected
for background by deducting the responses from the culture with medium only.
936 Kidney International (2010) 78, 934–940
or ig ina l a r t i c l e GH Struijk et al.: Immune responses under everolimus
from healthy control individuals (Po0.0005) as well as from
patients treated with P/CsA (Po0.005) or P/everolimus
(Po0.05) showed a significant increase. In contrast, patients
treated with P/MPA did not show a significant increase in
IL-2-producing cells after vaccination. In all patient groups,
the IL-2 response, represented as the difference between post-
and pre-vaccination numbers of cytokine-producing cells per
105 PBMCs, was significantly less as compared with healthy
control individuals.
Before vaccination, in most healthy control individuals,
IFN-g-producing cells were detectable upon stimulation with
TT in vitro (11.1±12.4). In contrast, in most patients, no or
only minimal numbers of cells producing IFN-g were
detectable before vaccination: P/CsA, 5.2±10.8; P/MPA,
1.4±2.9; and P/everolimus, 10.6±20.6. At 14 days after
vaccination, the mean number of IFN-g-producing cells
increased significantly in the healthy control individuals
(Po0.005) and in patients treated with P/CsA (Po0.05).
There was no significant increase in the mean number
of IFN-g-producing cells in patients receiving P/MPA or
P/everolimus. The IFN-g response, measured as the differ-
ence between post- and pre-vaccination numbers of cyto-
kine-producing cells per 105 PBMCs, was significantly
reduced in all patient groups as compared with healthy
control individuals.
In healthy control individuals and in all patient groups, no
or only minimal numbers of cells producing IL-4 were
detectable before vaccination: healthy control individuals,
0.3±0.5; P/CsA, 0.2±0.4; P/MPA, 0.1±0.4; and P/ever-
olimus, 2.0±3.1. At 14 days after vaccination, there was a
significant increase in the number of IL-4-producing cells in
healthy control individuals (Po0.0005) and in all patient
groups: P/CsA (Po0.05); P/MPA (Po0.05); and P/ever-
olimus (Po0.05). As compared with healthy control
individuals, the IL-4 response, as measured by the difference
in cytokine-producing cells post- and pre-vaccination, was
significantly inhibited in all patient groups.
In contrast to the IFN-g-producing cell numbers, the
number of TT-specific IL-2-producing cells at 14 days
after vaccination showed a fair correlation with the levels of
IgG antibodies against TT after vaccination in healthy
control individuals as well as in P/everolimus-treated
patients (r¼ 0.38 and 0.42, respectively; data not shown).
For IL-4-producing cells, a correlation was found in
the healthy control individuals only (r¼ 0.50, data not
shown).
B-cell phenotype
Mean (±s.d.) lymphocyte counts, total B cells, and B-cell
subsets are listed in Table 3. There was no significant
difference between total lymphocyte counts in either of the
patient groups compared with the healthy control indivi-
duals. The absolute B-cell number was significantly lower in
patients treated with P/MPA compared with healthy control
individuals (Po0.0005), whereas patients treated with P/CsA
or P/everolimus had slightly less B-cell numbers, though
not-significant, in peripheral blood as compared with
healthy control individuals. There was no difference in the
percentage naı¨ve (IgDþCD27) B cells, non-switched
memory (IgDþCD27þ ) B cells, and switched memory
(IgDCD27þ ) B cells within the total B-cell population
between either of the patient groups and healthy control
individuals (data not shown).
A fair degree of correlation was found between the
absolute number of B cells and IgG levels against TT after
vaccination both in healthy control individuals and in
P/everolimus-treated patients (r¼ 0.38 and 0.31, respectively;
data not shown). No significant correlation was found
between absolute B cells or B-cell subset counts and IgG
levels against PPS.
DISCUSSION
Here, we show that immunosuppressive drug therapy
consisting of P and everolimus allows for a significant rise
in the antigen-specific IgG antibody level in the primary
humoral immune response, and leaves secondary T-cell-
dependent and T-cell-independent immune responses intact.
However, treatment with P and MPA completely prevents the
generation of antibodies not only in primary but also in
secondary humoral immune responses. Treatment with P and
CsA inhibits the primary humoral immune response, but
permits significant rises in the antigen-specific IgG antibody
level in secondary immune responses. Cellular immune
responses against TT in vitro are significantly inhibited by all
these drug combinations, compared with healthy control
individuals. Patients treated with P/MPA show severely
reduced circulating B-cell numbers, which are normally
distributed between the main B-cell subsets.
Previously, we found no effect of CsA in combination
with P on primary T-cell-dependent humoral responses,14
which may be explained by the lower drug exposure as
compared with the strict areas under the curve (AUC)-
targeted drug dosing in the present study.19 The P/CsA
Table 3 | Number of total lymphocytes and B-lymphocyte subsets
Lymphocytes B cells Naive B cells Non-switched memory B cells Switched memory B cells
P/CsA 1.8±1.0 0.07±0.06 0.040±0.038 0.012±0.012 0.018±0.017
P/MPA 1.6±0.5 0.02±0.02*** 0.013±0.015** 0.002±0.001*** 0.004±0.003***
P/everolimus 1.8±0.7 0.07±0.05 0.041±0.027 0.013±0.011 0.017±0.013
HC 2.0±0.4 0.14±0.08 0.071±0.046 0.031±0.039 0.026±0.013
Abbreviations: CsA, cyclosporine; HC, healthy control individuals; MPA, mycophenolate sodium; P, prednisolone.
Statistical comparison of the mean (±s.d.) absolute number ( 109/l): *Po0.05, **Po0.005, ***Po0.0005 versus HC.
Kidney International (2010) 78, 934–940 937
GH Struijk et al.: Immune responses under everolimus o r ig ina l a r t i c l e
regimen significantly inhibited antigen-specific cellular res-
ponses against TT in vitro, which may be explained by the
property of CsA to inhibit transcription of several cytokines,
in particular IL-2 and IFN-g. Indeed, IFN-g production was
reduced in patients treated with calcineurin inhibitors
compared with healthy control individuals in one study,20
which was not confirmed in two other studies,10,21 probably
owing to differences in drug exposure.
The drug combination P/MPA completely inhibited the
capacity to mount both primary and secondary humoral
immune responses, which is in agreement with previous
studies.14,22 MPA may have suppressed the humoral immune
responses to some extent via its effect on T cells, as cellular
responses against TT in vitro were severely inhibited during
treatment with P/MPA. However, the T-cell-independent
humoral response against PPS was also severely reduced, also
suggesting at least a direct effect on B cells. The reduced
number of circulating memory B cell may have contributed
to this, as has been shown in patients after splenectomy.23
In vitro, MPA has been shown to inhibit B-cell proliferation
and IgG production, and to induce apoptosis in B cells.24
In P/everolimus-treated patients, the primary and secon-
dary humoral immune responses showed a significant rise
in the antigen-specific IgG antibody level after vaccination.
This is in line with recent findings of Araki et al.25 showing
that administration of everolimus to non-human primates
even enhanced memory T-cell responses to vaccination with
modified vaccinia virus. The renal transplant recipients
receiving P/everolimus are still protected against rejection
of their allograft may be because to the fact that everolimus
and other mammalian target of rapamycin-inhibitors induce
regulatory T cells, which specifically inhibit allo-specific
responses.26–28
Our findings are in agreement with those of Willcocks
et al.,15 who demonstrated similar humoral responses
after vaccination with PPS and influenza vaccines in renal
transplant recipients treated with a sirolimus-based as
compared with a calcineurin inhibitor-based immunosup-
pressive regimen. Here, we show that everolimus even
permits a primary immune response. However, the drug
did lower the antigen-specific cellular responses in vitro. In
contrast to previous reports,10,15 we studied a homogenous
cohort of renal transplant recipients, who received ever-
olimus with only a minimal dose of P (10 mg) and a strict
AUC-targeted drug dosing.19
In the P/everolimus-treated patients, there was a signi-
ficant increase in the IL-2 secretion, measured by ELISPOT,
after vaccination. We found a correlation between the
number of IL-2-producing cells and the IgG levels against
TT, suggesting that mainly these cells determine the
TT-specific antibody response, which is in agreement with
data by Litjens et al.29 regarding vaccination with the T-cell-
dependent Hepatitis B surface antigen. As has also been
demonstrated in two other studies,10,21 we did not find a
correlation between IFN-g production in vitro and humoral
responses against TT in healthy control individuals or in any
of the patient groups. In healthy control individuals, we
found a correlation between the number of TT-specific
IL-4-producing cells and IgG levels against TT 14 days after
vaccination, which supports the importance of T-cell help for
B-cell differentiation and IgG production by plasma cells.
We did not find a difference in the percentage of naı¨ve B
cells, non-switched memory B cells, and switched memory
B cells between either of the patient groups and healthy
control individuals. Only in P/everolimus-treated patients a
significant relationship between the number of switched
memory B cells and TT-specific IgG antibody levels was
found, which is in agreement with data found in HIV-
infected patients.30 The number of individuals tested in each
group may have been too small to detect more significant
relationships.
Several studies indicate that maintenance of immuno-
logical memory is impaired in immunosuppressed transplant
recipients. Renal transplant recipients vaccinated against
hepatitis A experienced a much more rapid decline of
antibodies as compared with healthy control individuals.31
Renal transplant recipients with preexisting immunity,
who were treated with maintenance therapy consisting of
CsA, azathioprine, and/or P, and who received a booster
vaccination at least 6 months after renal transplantation, all
developed protective tetanus antibody levels. However, 1 year
later, although still in the protective range, titers were
significantly lower compared with healthy control indivi-
duals.32 These observations suggest that protective immunity
that is induced after vaccination wanes more rapidly.
Although this issue was not addressed in the present study,
the finding of only minimal numbers of IFN-g-producing
cells before vaccination in all patient groups points towards
that direction.
In conclusion, double immunosuppressive drug therapy
consisting of P and everolimus allows for a significant rise in
the antigen-specific IgG antibody level in the primary
humoral immune response and leaves secondary T-cell-
dependent and T-cell-independent immune responses intact.
The drug combination P/CsA decreases the capacity to
mount a primary immune response, but allows for significant
rises in the antigen-specific IgG antibody level in secondary
immune responses. However, both primary and secondary
humoral responses are severely disturbed in renal transplant
recipients receiving the drug combination P/MPA, implying




The current study is a sub-study nested in an open randomized
multicenter trial in renal transplant recipients, to asses the long-term
effects of three different immunosuppressive agents, containing
CsA, MPA, or everolimus. Renal transplant recipients between 18
and 70 years, receiving a first or second renal transplantation
were eligible. The following patients were excluded: recipients
of a simultaneous pancreas kidney transplant or a double kidney
transplant, a third or fourth transplant, or a transplant from an
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human leukocyte antigen-identical sib; those having 450% (current
or historic) panel reactive antibodies; and patients who were
pregnant or unwilling to use adequate contraception during the
study. Patients were block-randomized per participating hospital by
a computer-generated randomization table. For the sub-study, only
patients who were included in one of the participating centers
(Amsterdam), who were not vaccinated against TT and PPS in the
previous 5 years, and who were in their second year after
transplantation with a stable glomerular filtration rate of at least
25 ml for the last 6 months were eligible. Subsequent, eligible
patients visiting the outpatient renal transplantation clinic were
asked to participate until the maximum number of participants per
group was reached.
A total of 36 patients were enrolled in the sub-study, 12 in each
arm. They were on double immunosuppressive maintenance therapy
consisting of P with CsA, MPA, or everolimus from 6 months after
transplantation. The patients all received P 10 mg per day orally.
Drug exposure to CsA, MPA, and everolimus were monitored by
calculating AUC. Target values of AUCs for CsA were 3250 ng h/ml.
The AUC targets for MPA were 70–85 mg h/ml and for everolimus
150mg h/ml. In all, 13 healthy individuals, matched for age and sex,
were included in the sub-study to serve as healthy control
individuals. Exclusion criteria were: use of immunosuppressive
drugs and vaccination against TT and PPS in the previous 5 years.
The healthy individuals were recruited via an advertisement. The
sub-study was approved by the local medical ethics committee and
separate written informed consent was obtained.
Vaccinations
Concomitant administration of three vaccines was performed
at the outpatient renal transplantation clinic by an independent
physician.
Vaccination with immunocyanin (Immucothel, Biosyn Arznei-
mittel GmbH, Fellbach, Germany), a stable modification of the
blood pigment hemocyanin from a sea snail (Megathura crenulata),
was performed to study the primary immune response to a protein
antigen. The vaccine was supplied as a lyophilized powder,
containing 1000mg immunocyanin, which was dissolved in NaCl
before administration.
TT (containing at least 80 IE TT per ml) was obtained from
Aventis Pasteur MSD (Brussels, Belgium). This protein antigen
elicits a secondary T-cell-dependent immune response.
Polyvalent Pneumococcal vaccine (Pneumovax, Merck Sharp
and Dohme, Haarlem, The Netherlands), is the 23-valent poly-
saccharide, sterile, liquid vaccine containing 25 mg of each of the
following capsular polysaccharides: types 1–5, 6B, 7F, 8, 9V, 10A,
11A, 12F, 18C, 19A, 19F, 20, 22, 23F, and 33F. By this vaccination
the secondary immune response to PPS was tested, which is mainly
T-cell independent.
One milligram of immunocyanin was administered subcuta-
neously. A total of 1 ml of Pneumovax and 0.5 ml of TT were
administered in the deltoid muscle of separate arms. Before as well
as 14 days after vaccination, blood was drawn to analyze antigen-
specific antibody production and -cellular reactivity.
Serology
IgG antibody levels against PPS, TT, and immunocyanin were
measured using enzyme-linked immunosorbent assay as described
previously.13,14,33,34 Antigen-specific antibody titers are represented
as the ratio between post- and pre-vaccination antibody levels.
B-cell phenotyping
Circulating B-cell subsets were determined at day 0. PBMCs were
isolated from peripheral blood by standard Ficoll (Fresenius Kabi
Norge AS, Oslo, Norway) density-gradient centrifugation and cryo-
preserved until analysis. Then, they were thawed and resuspended
in phosphate-buffered saline containing 0.5% (w/v) bovine serum
albumin and 0.01% (w/v) NaN3 (PBA). For surface staining, 300.000
PBMCs were incubated with fluorescent-labeled conjugated monoclonal
antibodies (concentrations according to manufacturer’s instructions)
for 30 min at 41C protected from light. AntiCD27-PE, IgD-FITC,
CD19-PerCP-Cy5.5, CD20-AP,C and CD3-Pe-Cy7 were all purchased
from BD Biosciences, San Jose, CA, USA. Next, cells were washed
in PBA and subsequently counted. Analysis was performed using a
FACS CANTO flowcytometer and BD FACSDiva (both BD Biosciences)
and FlowJo software (Treestar, Ashland, OR, USA).
A peripheral white blood cell count and differentiation was
performed in all participants. Absolute B-cell counts were calculated
by the percentage of CD3CD19þCD20þ cells multiplied by the
absolute lymphocyte number. The absolute B-cell subset counts
were calculated as the percentage of B-cell subset obtained from
flowcytometry multiplied by the absolute B-cell count.
ELISPOT assay
Cytokine production by PBMCs after antigen-specific stimulation
with TT was analyzed by ELISPOT assay. PBMCs were isolated from
peripheral blood by standard Ficoll density-gradient centrifugation
and cryopreserved until analysis. PBMCs from patients and healthy
control individuals were thawed, washed, and diluted to a
concentration of 2 106 cells/ml in RPMI 1640 with L-glutamin
(Gibco BRL, Life Technologies, Paisley, UK) supplied with 10%
heat-inactivated fetal calf serum (Gibco). Cells were pre-incubated
at 371C and 5% CO2 for 4 h in the absence or presence of TT (15 Lf/
ml RIVM, Bilthoven, The Netherlands) or phytohaemagglutinin
(0.1 mg/ml) in round bottom tubes (Micronic, McMurray, PA, USA).
PVDF-based membrane plates (Millipore, Billerica, MA, USA) were
coated with IL-4-, IL-2-, or IFN-g-specific antibodies as described in
the manufacturer’s protocol (Mabtech, Nacka Strand, Sweden). Pre-
incubated cells were diluted to a concentration of 1 105 cells/ml
and transferred to the coated plates (in triplicates) and left for 24
(IL-2 and IFN-g) or 48 h (IL-4) in a cell incubator at 371C and 5%
CO2. After the incubation period, the plates were washed and
cytokine production by PBMCs was detected by incubating the
plates with biotinylated secondary monoclonal antibodies, strepta-
vidin-ALP (Mabtech) and BCIP/NBT substrate (Sigma-Aldrich, St.
Louis, MO, USA). Spots were counted using ELISPOT analysis
software (A.EL.VIS GmbH, Hannover, Germany) and expressed as
positive cells per 105 stimulated PBMCs. The ELISPOT response in
phytohaemagglutinin-stimulated cultures served as positive control
and PBMCs cultured with medium only as negative control.
ELISPOT responses of the TT cultures were corrected for back-
ground by subtraction of the responses from the medium only
culture.
Statistical analysis
After logtransformation, between-group differences of continuous
variables were analyzed using an analysis of variance test or with a
weighted least squares analysis. After logtransformation, within-
group differences of continuous variables were analyzed using a
paired t-test. The Bonferroni correction was used to correct for
multiple comparisons. Univariate correlations between different
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variables within a group were assessed using Spearman’s rank
correlation test. A P-value of o0.05 was considered statistically
significant. For statistical analyses, GraphPad Prism 5 (GraphPad
Software, La Jolla, CA, USA) and SPSS 16.0 (SPSS, Chicago, IL,
USA) software programs were used.
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